Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ariana Appoints Dr Mariana Kuras as Chief Technology Officer

Published: Wednesday, August 22, 2012
Last Updated: Wednesday, August 22, 2012
Bookmark and Share
CTO appointment reinforces senior management expertise in biomarker industry.

Ariana Pharma has announced that it has appointed Dr. Mariana Kuras as its chief technology officer.

Mariana brings to Ariana eight years of experience at Biosystems International.

Whilst director of research, she was responsible for the development and validation of biomarker platform technologies in multi-million euro projects.

These technologies included the application of antibodies to various diseases, including oncology and neurodegenerative diseases.

Mariana and her team contributed towards the development of thousands of antibodies used on microarrays and to the patenting and publication of biomarker signatures and paving their route to market.

As a genomics and bioinformatics scientist at Pfizer Global Research and Development, Fresnes, France, Mariana has also been responsible for genomic studies.

She has also been an independent scientific expert for the sixth and seventh framework of the European Commission and vice-chair for the life sciences panel for sixth PCRD of the research and training networks for the European Commission.

She was awarded a PhD in biophysics and computational biology from the University of Illinois at Urbana-Champaign, USA.

“Mariana brings an exceptional level of both industrial and scientific experience to Ariana,” said Dr. Mohammad Afshar, president and CEO of Ariana Pharma.

Dr. Afshar continued, “Demand for our biomarker activity has continued to increase dramatically as a result of the drive in life science industries to personalized medicine. Mariana’s unique hands-on experience of both computational and experimental aspects of biomarker development will be a key asset to Ariana. She will help Ariana continue to meet our client’s growing needs.”

“Ariana has become one of the most promising international players in diagnostic and personalized medicine,” said Dr. Mariana Kuras.

Dr. Kuras continued, “By providing a validated solution to the challenge of combining heterogenous data from multiple sources with patient characteristics, Ariana will continue to grow as industry demand continues to increase and I am looking forward to adding my experience to the Ariana effort.”

KEM® - or Knowledge Extraction and Management - is an association rules-based (non-statistical) analytical technology that finds patient responder sub-populations and biomarker signatures that statistical methods are unable to detect.

KEM optimizes clinical trial inclusion/exclusion criteria thereby lowering the number of patients needed to reach clinical endpoints and saving sponsors both time and money.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ariana® Expands Operations to USA
Company also appoints James M. Shanahan VP business development of subsidiary “Ariana Data Intelligence, Inc.”
Monday, June 04, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Identified Compound Stops Cells Making Ribosomes
From study in yeast, researchers have identifed a compound that interferes with the assembly of ribosomes.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!